<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04051294</url>
  </required_header>
  <id_info>
    <org_study_id>2014707</org_study_id>
    <nct_id>NCT04051294</nct_id>
  </id_info>
  <brief_title>The Effect of Kombucha on Blood Sugar Levels in Humans</brief_title>
  <official_title>A Clinical Trial to Measure the Biochemical Response of Kombucha Tea in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Missouri-Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Missouri-Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      As a phase 0 clinical trial, we will learn how kombucha influences glucose metabolism in
      humans.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consumption of kombucha, a fermented tea beverage, has been promoted for a wide range of
      health benefits. However, a systematic literature review (Kapp &amp; Sumner, 2019) revealed a
      lack of evidence for human health benefit. Despite the lack of evidence, U.S. retail sales of
      kombucha and other fermented beverages have increased 37.4% in 2017, and kombucha is the
      fastest growing product in the functional beverage market.

      As a phase 0 clinical trial, we will learn how kombucha influences glucose metabolism in
      humans. We plan for 20 subjects to take part in this study.

      This is a randomized-controlled counter-balanced study design. Subjects will be asked to
      complete 4 in-person visits over 2 months time (twice per month). At the first visit,
      subjects will be randomized into one of four groups. At each subsequent visit, subjects will
      be randomized into one of the remaining groups until they have completed each arm.

      Arms (at least 5 subjects in each arm, minimum total=20 subjects)

        1. Intervention group 1: commercial kombucha: drink 8oz kombucha

        2. Intervention group 2: brewed kombucha: drink 8oz kombucha

        3. Control group: drink 8oz tea (the same type as used to brew the kombucha)

        4. Control group 2: drink 8oz tap water
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting blood glucose level</measure>
    <time_frame>Baseline</time_frame>
    <description>Blood drawn following a 10-12 hour fast.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting insulin level.</measure>
    <time_frame>Baseline</time_frame>
    <description>Blood drawn following a 10-12 hour fast.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood glucose level</measure>
    <time_frame>3 hour</time_frame>
    <description>Oral glucose tolerance test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin level</measure>
    <time_frame>3 hour</time_frame>
    <description>Oral glucose tolerance test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Glucose</condition>
  <condition>Glucose Metabolism Disorders (Including Diabetes Mellitus)</condition>
  <condition>Blood Sugar; High</condition>
  <arm_group>
    <arm_group_label>Intervention group 1: commercial kombucha</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8oz</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention group 2: brewed kombucha</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8oz</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group 1: tea</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8oz</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group 2: water</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>8oz</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Commercial kombucha tea</intervention_name>
    <description>Commercially-available kombucha tea.</description>
    <arm_group_label>Intervention group 1: commercial kombucha</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Brewed kombucha tea</intervention_name>
    <description>Kombucha tea brewed</description>
    <arm_group_label>Intervention group 2: brewed kombucha</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control: Tea</intervention_name>
    <description>Tea brewed in our lab.</description>
    <arm_group_label>Control group 1: tea</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control: Water</intervention_name>
    <description>Tap water</description>
    <arm_group_label>Control group 2: water</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women ages 30-65 years old

          -  English-speaking

          -  Have transportation to campus

          -  Overweight (BMI &gt;= 25 kg/m2) or obese (BMI &gt;=30 kg/m2)

        Exclusion Criteria:

          -  Currently use any type of nicotine product

          -  A diagnosis of any of the following:

               -  Diabetes (type 1 or 2)

               -  Cancer

               -  COPD

               -  Chronic alcoholism

               -  Peripheral vascular disease

               -  Autoimmune disease

               -  Chronic kidney disease

          -  Pregnant or breastfeeding

          -  Prescribed medication for insulin, glucose-lowering drugs, or steroids, such as
             prednisone

          -  Have routinely taken prebiotic or probiotic supplements in the past 3 months

          -  Have routinely consumed any of the following more than one time per week in the past
             month: kombucha, kefir, yogurt, kimchi, cottage cheese, raw apple cider vinegar (with
             the &quot;mother&quot;), sauerkraut, kvass.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie M Kapp, MPH, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Missouri-Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julie M Kapp, MPH, PhD</last_name>
    <phone>5738843684</phone>
    <email>kappj@health.missouri.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Missouri</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>tea_study@health.missouri.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 7, 2019</study_first_submitted>
  <study_first_submitted_qc>August 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2019</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Missouri-Columbia</investigator_affiliation>
    <investigator_full_name>Julie Kapp</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>kombucha</keyword>
  <keyword>kombucha tea</keyword>
  <keyword>tea</keyword>
  <keyword>fermented food</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

